From Startup Hype to Federal Court: Business Valuation and Expert Witnesses in the Theranos Trial

United States v. Holmes & Balwani: A High-Stakes Business Valuation Case

The United States v. Holmes & Balwani case underscores the vital role of business valuation and expert witnesses in exposing corporate fraud. Theranos, once a high-profile Silicon Valley startup, falsely claimed its technology could run comprehensive blood tests from a single drop. Between 2010 and 2015, Elizabeth Holmes and Ramesh “Sunny” Balwani misled investors and partners about the company’s capabilities and financial status, artificially inflating its valuation. Their actions led to multiple convictions for wire fraud and conspiracy.

In 2025, the Ninth Circuit upheld their convictions and $452 million restitution order, despite challenges involving expert witness testimony, valuation methods, and financial loss calculations. This landmark case highlights the importance of accurate business valuation and expert analysis in fraud investigations, serving as a cautionary tale for investors and legal professionals alike.

How the Theranos Case Unfolded: Key Legal and Financial Turning Points

1. Founding and Fraudulent Valuation Strategy:

   • Elizabeth Holmes launches Theranos, promoting a breakthrough blood-testing technology.
   • Alongside COO Ramesh “Sunny” Balwani, she markets the company using inflated claims that significantly distort Theranos’s business valuation, attracting major investments.

2. Media Exposure and Regulatory Fallout:

   • Media investigations reveal that Theranos’s technology does not work as promised.
   • The company’s multibillion-dollar valuation is called into question, triggering regulatory and legal scrutiny.

3. Criminal Charges and Federal Indictments:

   • A federal criminal investigation begins. In June 2018, Holmes and Balwani are indicted for conspiracy and wire fraud charges rooted in their fraudulent inflation of Theranos’s value and false financial projections.

4. Trial Convictions and Sentencing Outcomes:

   • Separate jury trials are held in federal court. Holmes is convicted in January 2022 of defrauding investors based on misleading valuation claims.
   • Balwani is convicted in July 2022 on all counts, including investor and patient fraud.
   • Late 2022, both are sentenced, Holmes to 135 months, Balwani to 155 months. They are jointly ordered to pay $452 million in restitution, a figure based on expert assessments of investor losses tied to Theranos’s false valuation.

5. Expert Testimony and Financial Loss Assessments:

   • The court evaluates financial harm using expert testimony and forensic analysis, rejecting claims that Theranos stock had residual value after the fraud.

6. Judicial Rulings Upheld:

   • The Ninth Circuit affirms the convictions and restitution order, holding that any errors in admitting expert or technical testimony were harmless.
   • The court reinforces that investors relied on misrepresented business valuation metrics in making decisions.

Business Valuation Experts and More: Witnesses in the Theranos Trial

In the trials of Elizabeth Holmes and Ramesh “Sunny” Balwani, expert witnesses provided testimony critical to the proceedings.

1. Business Valuation and Forensic Accounting Expert Witness:

   • Experts in this category analyzed Theranos’s financial statements and projections.
   • Provided insights into the company’s financial health, revealing discrepancies between reported revenues and actual financial performance, which were pivotal in illustrating the misrepresentation to investors.

2. Laboratory Expert Witness:

   • Individuals such as Dr. Kingshuk Das, who served as Theranos’s laboratory director, testified about the accuracy and reliability of Theranos’s blood-testing devices.
   • Dr. Das concluded that the devices were “unsuitable for clinical use,” highlighting significant deficiencies in the technology.

3. Regulatory Issues Expert Witness:

   • Witnesses with expertise in regulatory compliance discussed findings from agencies like the Centers for Medicare and Medicaid Services (CMS).
   • The CMS report was used to demonstrate Theranos’s regulatory shortcomings and was deemed relevant to assessing Holmes’s knowledge and intent regarding the laboratory’s conditions.

What the Theranos Case Teaches About Valuation and Expert Oversight

1. Misleading Business Valuation Can Lead to Criminal Liability

   • The Theranos case shows that inflated financial projections and false representations of company value can move beyond civil liability into federal criminal charges.
   • Startups and executives must ensure that all valuation-driving claims are grounded in verifiable data.

2. Expert Witness Qualifications Matter Under Rule 702

   • Courts closely scrutinize whether witnesses are properly qualified as The Ninth Circuit acknowledged concerns about expert-like testimony from unqualified witnesses but deemed any such errors harmless in this instance.
   • Always follow Daubert standards for admitting expert witness testimony.

3. Investor Confidence Hinges on Technology Validation and Financial Transparency

   • Theranos’s downfall was triggered by internal knowledge of faulty technology and external claims of operational success.
   • Forensic and valuation experts play a critical role in detecting and documenting gaps between actual performance and public representations.

4. Expert Witnesses Are Key in Complex Financial and Technical Fraud Cases

   • Whether testifying on lab accuracy, regulatory compliance, or financial loss, expert witnesses help courts understand highly specialized subject matter.
   • Their analysis often determines how damages are calculated and whether valuation claims are credible.

Conclusion

The United States v. Holmes & Balwani case illustrates the legal implications that can arise when a company’s business valuation is basedm on unsupported financial projections and unverified operational claims. The court proceedings examined how Theranos’s representations to investors contributed to an inflated valuation, ultimately leading to convictions for wire fraud and a $452 million restitution order. The case highlights the importance of accurate financial disclosures and substantiated valuation metrics in investor-facing communications.

Expert witnesses played a significant role in the judicial process by helping clarify complex technical and financial matters. Testimony from laboratory directors, regulatory specialists, and forensic accountants contributed to the court’s understanding of Theranos’s operational and financial practices. This case demonstrates the value of expert witness input in cases involving allegations of financial misrepresentation and emphasizes the intersection between expert analysis and business valuation in litigation settings.